105 related articles for article (PubMed ID: 3219056)
1. [The antineoplastic action of o-substituted [1,2-bis(4-hydroxyphenyl)-ethylenediamine]dichloroplatinum (II) complexes and their methylethers].
Karl J; Schönenberger H
Arch Pharm (Weinheim); 1988 Jul; 321(7):405-10. PubMed ID: 3219056
[No Abstract] [Full Text] [Related]
2. Tumor-inhibiting [1,2-bis(fluorophenyl)ethylenediamine]platinum(II) complexes. V. Synthesis and evaluation of enantiomeric [1,2-bis-(4-fluorophenyl)ethylenediamine]dichloroplatinum(II) complexes.
vom Orde HD; Reile H; Müller R; Gust R; Bernhardt G; Spruss T; Schönenberger H; Burgemeister T; Mannschreck A
J Cancer Res Clin Oncol; 1990; 116(5):434-8. PubMed ID: 2229132
[TBL] [Abstract][Full Text] [Related]
3. Tumor inhibiting properties of stereoisomeric [1,2-bis(3-hydroxyphenyl)ethylenediamine]dichloroplatinum(II)-compl exe s, Part I: Synthesis.
Jennerwein M; Gust R; Müller R; Schönenberger H; Engel J; Berger MR; Schmähl D; Seeber S; Osieka R; Atassi G
Arch Pharm (Weinheim); 1989 Jan; 322(1):25-9. PubMed ID: 2730286
[TBL] [Abstract][Full Text] [Related]
4. Tumor inhibiting properties of stereoisomeric [1,2-bis(3-hydroxyphenyl) ethylenediamine]dichloroplatinum(II)-complexes, Part II: Biological properties.
Jennerwein M; Gust R; Müller R; Schönenberger H; Engel J; Berger MR; Schmähl D; Seeber S; Osieka R; Atassi G
Arch Pharm (Weinheim); 1989 Feb; 322(2):67-73. PubMed ID: 2730292
[TBL] [Abstract][Full Text] [Related]
5. Mammary tumor inhibiting properties of the (S,S)-configurated [1,2-bis(4-hydroxyphenyl)ethylenediamine]dichloroplatinum(II) complex.
Spruss T; Gust R; Müller R; Engel J; Schönenberger H
Arch Pharm (Weinheim); 1990 Feb; 323(2):99-102. PubMed ID: 2334275
[TBL] [Abstract][Full Text] [Related]
6. Platinum and palladium complexes containing ethylenediamine derivatives as carrier ligands and their antitumor activity.
Lee K; Tashiro T; Noji M
Chem Pharm Bull (Tokyo); 1994 Mar; 42(3):702-3. PubMed ID: 8004720
[TBL] [Abstract][Full Text] [Related]
7. Tumor inhibiting [1,2-bis(difluorophenyl)ethylenediamine]dichloroplatinum (II) complexes, I: Synthesis.
Müller R; Schickaneder E; Jennerwein M; Reile H; Spruss T; Engel J; Schönenberger H
Arch Pharm (Weinheim); 1991 Feb; 324(2):115-20. PubMed ID: 1854235
[TBL] [Abstract][Full Text] [Related]
8. [Antitumor platinum(II) complexes with substituted 2-aminomethylpyridine ligands].
Brunner H; Nerl G; von Angerer E; Knebel N
Arch Pharm (Weinheim); 1991 Oct; 324(10):779-84. PubMed ID: 1805710
[TBL] [Abstract][Full Text] [Related]
9. Different response of murine and human mammary tumour models to a series of diastereoisomeric [1,2-bis(difluorophenyl) ethylenediamine]dichloroplatinum(II) complexes.
Spruss T; Bernhardt G; Schickaneder E; Schönenberger H
J Cancer Res Clin Oncol; 1991; 117(5):435-43. PubMed ID: 1890139
[TBL] [Abstract][Full Text] [Related]
10. [1,2-Bis(2-hydroxyphenyl)ethylenediamine]dichloroplatinum(II), a new compound for the therapy of ovarian cancer. II. Synthesis and preliminary testing of the enantiomeric complexes.
Bernhardt G; Gust R; Reile H; vom Orde HD; Müller R; Keller C; Spruss T; Schönenberger H; Burgemeister T; Mannschreck A
J Cancer Res Clin Oncol; 1992; 118(3):201-8. PubMed ID: 1548285
[TBL] [Abstract][Full Text] [Related]
11. Aqua[1,1-bis(4-hydroxyphenyl)-1,2-diamino-2-phenylethane]- sulfatoplatinum(II), a new compound for the treatment of the mammary carcinoma.
Gust R
Arch Pharm (Weinheim); 1994 Jan; 327(1):49-54. PubMed ID: 8117188
[TBL] [Abstract][Full Text] [Related]
12. Stereoisomeric [1,2-bis(3-hydroxyphenyl)ethylenediamine]platinum(II) complexes, Part III: Evaluation of the mammary tumor inhibiting properties.
Schertl S; Gust R; Müller R; Spruss T; Schönenberger H
Arch Pharm (Weinheim); 1992 Feb; 325(2):113-8. PubMed ID: 1605715
[TBL] [Abstract][Full Text] [Related]
13. Reduction of the estrogenic side effects of the mammary tumor-inhibiting drug [1,2-bis(2,6-dichloro-4-hydroxyphenyl)- ethylenediamine]dichloroplatinum(II) by variation of ring substituents.
Gust R; Karl J; Faderl M; Schönenberger H
Arch Pharm (Weinheim); 1995 May; 328(5):457-63. PubMed ID: 7611841
[TBL] [Abstract][Full Text] [Related]
14. Does [meso-1,2-bis(2,6-dichloro-4-hydroxyphenyl)ethylenediamine]- dichloroplatinum(II) act on the hormone-sensitive, murine breast cancer as a biological response modifier? Part II. Studies on the influence of [meso-1,2-bis(2,6-dichloro-4-hydroxyphenyl)ethylenediamine] dichloroplatinum(II) on the specific immune defense in MXT-M-3,2 breast cancer bearing mice.
Schlemmer R; Spruss T; Bernhardt G; Schönenberger H
Arch Pharm (Weinheim); 2000 Dec; 333(12):397-403. PubMed ID: 11199469
[TBL] [Abstract][Full Text] [Related]
15. Synthesis, mutagenicity, binding to pBR 322 DNA and antitumour activity of platinum(II) complexes with ethambutol.
Coluccia M; Fanizzi FP; Giannini G; Giordano D; Intini FP; Lacidogna G; Loseto F; Mariggio MA; Nassi A; Natile G
Anticancer Res; 1991; 11(1):281-7. PubMed ID: 2018362
[TBL] [Abstract][Full Text] [Related]
16. Aqua[1-(2,6-dichloro-4-hydroxyphenyl)-2- phenylethylenediamine](sulfato)platinum-(II) complexes with variable substituents in the 2-phenyl ring. 1. Synthesis and antitumor and estrogenic properties.
Gust R; Burgemeister T; Mannschreck A; Schönenberger H
J Med Chem; 1990 Sep; 33(9):2535-44. PubMed ID: 2391694
[TBL] [Abstract][Full Text] [Related]
17. A water-soluble 1,2-diaminocyclohexaneplatinum(II) complex containing procaine hydrochloride: synthesis and antiproliferative activity in vitro.
Cafaggi S; Esposito M; Parodi B; Viale M
Pharmazie; 1994 Aug; 49(8):617-8. PubMed ID: 7938154
[No Abstract] [Full Text] [Related]
18. Comparison of the effectivity of two diaminocyclohexane Pt-complexes.
Balázová E; Hrubisko M; Ujházy V
Neoplasma; 1985; 32(5):537-42. PubMed ID: 4069288
[TBL] [Abstract][Full Text] [Related]
19. New platinum (II) and platinum (IV) complexes with 1,2-diaminocyclohexane. Synthesis and in vitro and in vivo antitumour evaluation.
Craciunescu DG; Furlani Candiani A; Scarcia V; Doadrio A; Ghirvu C
J Pharm Belg; 1985; 40(2):79-84. PubMed ID: 4009393
[No Abstract] [Full Text] [Related]
20. Tumor inhibiting [1,2-bis(fluorophenyl)ethylenediamine]platinum(II) complexes. Part IV: Biological evaluation--in vivo studies on the P 388 leukemia.
Reile H; Spruss T; Bernhardt G; Müller R; Gust R; Schönenberger H
Arch Pharm (Weinheim); 1991 Jul; 324(7):405-9. PubMed ID: 1763951
[No Abstract] [Full Text] [Related]
[Next] [New Search]
